27 November 2019
Leonardo da Vinci is the first airport in the world to adopt Biovitae lamps, registered as a medical device by the Ministry of Health

Leonardo da Vinci is the first airport in the world to install Biovitae bactericidal lighting devices, able to reduce the risk of infection for workers and passengers and limit the phenomena of antibiotic resistance, at its first aid centre (reception room, emergency medical examination room with operating table, examination report room, patient hospitalisation room)

Biovitae is the only patented LED technology that, thanks to a combination of light frequencies, kills all bacteria (Gram+, Gram-, spores, mould and fungi) and sanitises the environment without making it sterile and without, therefore, weakening the immune system.

Biovitae is an LED light that, unlike UV, is completely safe for humans and does not require special protective measures.

Antibiotic resistance is one of the biggest health emergencies of our time.

Of the 33 thousand deaths that happen each year in the EU due to infections caused by bacteria that are resistant to antibiotics, more than ten thousand are registered in Italy. A negative track record, according to data provided by the Istituto Superiore di Sanità (Italian National Institute of Health - ISS) during the World Antibiotic Awareness Week. Respecting hygiene standards and identifying preventive actions are therefore increasingly important.

With the installation of Biovitae, the Aeroporti di Roma company has decided to embark on a serious path in the fight against infection by taking on board the alarm raised by researchers of the PANDHUB project, carried out by VTT (Technical Research Centre) - Finland's leading public research centre - in collaboration with the University of Nottingham, among others, and launched in November 2014 to assess the risks of spreading diseases within transport hubs around the world. The final objective of the three-year research project, financed with €3.1 million of European Funds, is to develop a prevention model and a plan of action in the event of a crisis.

Today, at Fiumicino, the brilliant results of this experiment are being introduced.

“Thanks to the Biovitae technology,” declared CEO of Adr, Ugo de Carolis, “the reduction of the bacterial load in the test rooms was more than 60%, and the reduction in spaces with good bacterial hygiene almost doubled, going from 42% to 83%. From today we can consider the first aid centre at Fiumicino airport as a place where the microbiological risk for passengers and health workers is substantially eliminated”.

“We are very pleased that a 100% Italian patent has been adopted by ADR that, as the first airport in the world to do so, understood the importance of doing something concrete for the fight against infections and antibiotic resistance. I hope that this is the first step of a continuous collaboration and that this virtuous path can be a stimulus for airports all over the world,” stated Mauro Pantaleo, CEO of P&P Patents and Technologies, the company holding the patent.

ADR is evaluating the opportunities of trialling the product within the Terminals and in the passenger boarding and disembarkation areas.



Aeroporti di Roma, an Atlantia Group company, manages and develops the Fiumicino and Ciampino airports in Rome and performs other activities related and complimentary to airport management. Fiumicino operates through two passenger terminals. It is dedicated to business and leisure clients on national, international and intercontinental routers. Ciampino is mainly used by low-cost airlines, by express couriers and for General Aviation operations. In 2018 the ADR airport system registered 48.8 million passengers, with over 230 destinations across the world that can be accessed from Rome thanks to around 100 airlines operating in the two airports. In 2019 the Airports Council International Europe awarded Leonardo da Vinci with the “Best Airport 2018”. For the second year in a row, Fiumicino has been confirmed as the top-ranked of 20 European airports with over 25 million passengers for its quality of service, technological innovation, and the efficiency of its infrastructure. This adds to the “Airport Service Quality” award granted to the Leonardo da Vinci airport in 2019, for the second year in a row, by the Airports Council International World as the most appreciated airport in Europe amongst hubs with more than 40 million passengers. ADR’s management skills have also been confirmed during 2019 by the awards received from Skytrax, the main international society for the rating and evaluation of the airport sector, which verified that Fiumicino achieved 4 Skytrax stars in 2017.



Press and New Media Office
+39 345 1283176 +39 335 1753281 +39 327 5588358 +39 338 2098246 +39 348 2270950



The P&P Patents and Technologies Group was born with the objective of carrying out activities in the health sector in the field of strategic consultancy and to develop - through its investees - patents relating to technologies in the field of health and well-being for the prevention and control of infections.
The portfolio currently consists of eight proprietary patents, with technologies ranging from medical devices to solutions for the efficient administration of drugs and supplements. P&P Patents and Technologies is a member of POPS IS – Private Organisations for Patient Safety – Injection Safety, a round table set up and co-ordinated by the World Health Organisation to promote collaboration between the private sector and institutions, aimed at improving health practices for the prevention of infections.


Press Office P&P Patents and Technologies
+39 3383566988